Ring, Aaron Michael - Yale University - Biological & Biomedical Sciences

个人简介

Aaron Ring received his undergraduate training at Yale University and entered the Stanford Medical Scientist Training Program for his MD and PhD degrees. At Stanford, he worked in the laboratories of K. Christopher Garcia and Irving Weissman to use structure-based protein engineering to develop new cytokine and immune checkpoint therapies for cancer. He additionally developed novel methodologies in protein engineering to create biologic agents against challenging targets such as G protein coupled receptors (GPCRs). Aaron joined the faculty of the Yale Department of Immunobiology in 2016 as the Robert T. McCluskey Yale Scholar. The focus of his research is to understand and manipulate the activity of immune receptors using structural and combinatorial biology approaches. MD/PhD Stanford University School of Medicine, Structural Biology (2016) BS Yale University, Molecular Biophysics and Biochemistry (2008) MS Yale University, Molecular Biophysics and Biochemistry (2008)

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Chhabra A*, Ring AM*, Weiskopf K*, Schnorr PJ, Gordon SA, Le AC, Kwon H, Ring NG, Volkmer J, Ho PY, Tseng S, Weissman IL, Shizuru JA. Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Sci. Transl. Med. 2016. 8(351). Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Maute RL, Gordon SG, Mayer AT, McCracken MN, Natarajan A, Ring NG, Kimura R, Tsai JM, Manglik A, Kruse AC, Gambhir SS, Weissman IL, Ring AM. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci, U S A. 2015. 112(47):6506-14. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity. Mitra S*, Ring AM*, Amarnath S, Spangler JB, Li P, Ju W, Fischer S, Oh J, Spolski R, Weiskopf K, Kohrt H, Foley JE, Rajagopalan S, Long EO, Fowler DH, Waldmann TA, Garcia KC, and Leonard WJ. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity. 2015. 42: 826-838. Engineered SIRPα variants as immunotherapeutic adjuvants to anti-cancer antibodies. Weiskopf K*, Ring AM*, Ho CCM, Volkmer J, Levin AM, Volkmer AK, Ozkan E, Fernoff NB, van de Rijn M, Weissman IL, and Garcia KC. Engineered SIRPα variants as immunotherapeutic adjuvants to anti-cancer antibodies. Science. 2013. 341(6141): 88-91. Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody. Ring AM, Manglik A, Kruse AC, Enos MD, Weis WI, Garcia KC, and Kobilka BK. Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody. Nature. 2013. 502(7472):575-579. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Kruse AC*, Ring AM*, Manglik A, Hu J, Hu H, Eitel K, Hübner H, Pardon E, Valant C, Sexton PM, Christopoulos A, Felder CC, Gmeiner P, Steyaert J, Weis WI, Garcia KC, Wess J, Kobilka BK. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature. 2013. 504(7478): 101-6. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Ring AM, Lin JX, Feng D, Mitra S, Rickert M, Bowman GR, Pande VS, Li P, Moraga I, Spolski R, Ozkan E, Leonard WJ, and Garcia KC. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nature Immunology. 2012. 13(12): 1187-95. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine.’ Levin AM*, Bates DL*, Ring AM*, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P, Pande VS, Fathman CG, Boyman O, and Garcia KC. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine.’ Nature. 2012. 484(7395): 529–533. Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL: PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017 May 17; 2017 May 17. PMID: 28514441 Mayer AT, Natarajan A, Gordon SR, Maute RL, McCracken MN, Ring AM, Weissman IL, Gambhir SS: Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. J Nucl Med. 2017 Apr; 2016 Dec 15. PMID: 27980047 Pascolutti R, Sun X, Kao J, Maute RL, Ring AM, Bowman GR, Kruse AC: Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. Structure. 2016 Oct 4; 2016 Sep 8. PMID: 27618663 Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, Kimura R, Tsai JM, Manglik A, Kruse AC, Gambhir SS, Weissman IL, Ring AM: Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A. 2015 Nov 24; 2015 Nov 10. PMID: 26604307 Rinehart J, Vázquez N, Kahle KT, Hodson CA, Ring AM, Gulcicek EE, Louvi A, Bobadilla NA, Gamba G, Lifton RP: WNK2 kinase is a novel regulator of essential neuronal cation-chloride cotransporters. J Biol Chem. 2011 Aug 26; 2011 Jul 6. PMID: 21733846 Kahle KT, Ring AM, Lifton RP: Molecular physiology of the WNK kinases. Annu Rev Physiol. 2008. PMID: 17961084 Ring AM, Leng Q, Rinehart J, Wilson FH, Kahle KT, Hebert SC, Lifton RP: An SGK1 site in WNK4 regulates Na+ channel and K+ channel activity and has implications for aldosterone signaling and K+ homeostasis. Proc Natl Acad Sci U S A. 2007 Mar 6; 2007 Feb 22. PMID: 17360471 Ring AM, Cheng SX, Leng Q, Kahle KT, Rinehart J, Lalioti MD, Volkman HM, Wilson FH, Hebert SC, Lifton RP: WNK4 regulates activity of the epithelial Na+ channel in vitro and in vivo. Proc Natl Acad Sci U S A. 2007 Mar 6; 2007 Feb 26. PMID: 17360470 Kahle KT, Rinehart J, Ring A, Gimenez I, Gamba G, Hebert SC, Lifton RP: WNK protein kinases modulate cellular Cl- flux by altering the phosphorylation state of the Na-K-Cl and K-Cl cotransporters. Physiology (Bethesda). 2006 Oct. PMID: 16990453